Picture of NuVasive logo

NUVA — NuVasive News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid Cap

NuVasive Inc expected to post earnings of 39  cents a share - Earnings Preview

* NuVasive Inc  NUVA.OQ   NUVA.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 4. 
    * The San Diego California-based  company is expected to
report  a
2.5% increase in revenue to $277.973 million from $271.25
million a year ago, according to the mean estimate from 14
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for NuVasive Inc is for
earnings of 39 cents per share. For the same quarter last year,
the company reported earnings of 37 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 7
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months. ​
    * Wall Street's median 12-month price target for NuVasive
Inc is
$64​, above​ its last closing price of $53.99. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  0.49        0.49       0.40      Missed  -17.5
 Sep. 30 2021  0.52        0.53       0.32      Missed  -40.1
 Jun. 30 2021  0.46        0.44       0.60      Beat    35​
 Mar. 31 2021  0.36        0.35       0.37      Beat    5.9
 ​​Dec.        0.55        0.55       0.59      Beat    6.4
 31 2020                                                
 Sep. 30 2020  0.23        0.24       0.55      Beat    130.9​
 Jun. 30 2020  -0.40       -0.47      -0.40     Beat    15.6
 Mar. 31 2020  0.38        0.41       0.48      Beat    17.3
 This summary was machine generated May 3 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on NuVasive

See all news